Loading…
Examination of purification methods and development of intravitreal injection of triamcinolone acetonide
Intravitreal injection of triamcinolone acetonide (TA) is used in ophthalmic treatment, but the reliability of commercially available TA preparations has still not been established. We evaluated two previously reported purification methods, and developed a more reliable TA injection which can be pre...
Saved in:
Published in: | Japanese journal of ophthalmology 2005-09, Vol.49 (5), p.384-387 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c441t-e8a8de078503c12e75b55d9af3350a02a3e34a99a6d6cd015faf34c351aca81e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c441t-e8a8de078503c12e75b55d9af3350a02a3e34a99a6d6cd015faf34c351aca81e3 |
container_end_page | 387 |
container_issue | 5 |
container_start_page | 384 |
container_title | Japanese journal of ophthalmology |
container_volume | 49 |
creator | Oishi, Masako Maeda, Shinichiro Nakamura, Ayumi Kurokawa, Nobuo Ohguro, Nobuyuki Tano, Yasuo |
description | Intravitreal injection of triamcinolone acetonide (TA) is used in ophthalmic treatment, but the reliability of commercially available TA preparations has still not been established. We evaluated two previously reported purification methods, and developed a more reliable TA injection which can be prepared in a hospital pharmacy.
We tested the two methods previously reported for purifying commercial TA preparations, the sedimentation and the filtration and backflushing methods. We developed a new TA injection made of pure TA suspended in 0.5% sodium hyaluronate. We measured the TA content in each preparation by high-performance liquid chromatography to evaluate the three methods.
In the sedimentation purification method, the TA content of a nominal 4-mg preparation varied from 1.43 to 7.37 mg, and the average recovery rate was 91.6%. In the filtration and backflushing method, TA content was 0.10-10.33 mg and recovery was 59.5%. In the TA injection we developed, the mean TA content was 102.5% (SD, 0.24; CV, 2.9%). The stability of this preparation was 99% after sterilization, and 97% after 3 months of storage.
The results of our investigation showed that the purification methods used for commercial preparations are simple and easy but not precise enough for an intravitreal injection. In contrast, the TA injection prepared by our method is reliable, stable, and safe enough for clinical use. |
doi_str_mv | 10.1007/s10384-004-0226-0 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68625641</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68625641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-e8a8de078503c12e75b55d9af3350a02a3e34a99a6d6cd015faf34c351aca81e3</originalsourceid><addsrcrecordid>eNpdkU1LBDEMhosoun78AC8yePA2mrbT2dmjiF8geNFziW0Gu8y0a9sR_fd22RXBQwghz_sS8jJ2yuGSA8yvEgfZNTVAKSHaGnbYjLdc1kI07S6bAQheK67UATtMaQkFFFLss4MCdfOinbH32y8cncfsgq9CX62m6HpnNvNI-T3YVKG3laVPGsJqJJ_XnPM54qfLkXAow5LMr0OODkfjfBiCpwoN5eCdpWO21-OQ6GTbj9jr3e3LzUP99Hz_eHP9VJum4bmmDjtLMO8USMMFzdWbUnaBvZQKEARKkg0uFtja1ljgqi-rxkjF0WDHSR6xi43vKoaPiVLWo0uGhgE9hSnptmuFahtewPN_4DJM0ZfbtJBcKCHVokB8A5kYUorU61V0I8ZvzUGvM9CbDHR5rV5noKFozrbG09tI9k-xfbr8Ab9Og5s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>231252359</pqid></control><display><type>article</type><title>Examination of purification methods and development of intravitreal injection of triamcinolone acetonide</title><source>Springer Nature</source><creator>Oishi, Masako ; Maeda, Shinichiro ; Nakamura, Ayumi ; Kurokawa, Nobuo ; Ohguro, Nobuyuki ; Tano, Yasuo</creator><creatorcontrib>Oishi, Masako ; Maeda, Shinichiro ; Nakamura, Ayumi ; Kurokawa, Nobuo ; Ohguro, Nobuyuki ; Tano, Yasuo</creatorcontrib><description>Intravitreal injection of triamcinolone acetonide (TA) is used in ophthalmic treatment, but the reliability of commercially available TA preparations has still not been established. We evaluated two previously reported purification methods, and developed a more reliable TA injection which can be prepared in a hospital pharmacy.
We tested the two methods previously reported for purifying commercial TA preparations, the sedimentation and the filtration and backflushing methods. We developed a new TA injection made of pure TA suspended in 0.5% sodium hyaluronate. We measured the TA content in each preparation by high-performance liquid chromatography to evaluate the three methods.
In the sedimentation purification method, the TA content of a nominal 4-mg preparation varied from 1.43 to 7.37 mg, and the average recovery rate was 91.6%. In the filtration and backflushing method, TA content was 0.10-10.33 mg and recovery was 59.5%. In the TA injection we developed, the mean TA content was 102.5% (SD, 0.24; CV, 2.9%). The stability of this preparation was 99% after sterilization, and 97% after 3 months of storage.
The results of our investigation showed that the purification methods used for commercial preparations are simple and easy but not precise enough for an intravitreal injection. In contrast, the TA injection prepared by our method is reliable, stable, and safe enough for clinical use.</description><identifier>ISSN: 0021-5155</identifier><identifier>EISSN: 1613-2246</identifier><identifier>DOI: 10.1007/s10384-004-0226-0</identifier><identifier>PMID: 16187038</identifier><language>eng</language><publisher>Japan: Springer Nature B.V</publisher><subject>Chromatography, High Pressure Liquid ; Glucocorticoids - analysis ; Glucocorticoids - chemistry ; Glucocorticoids - isolation & purification ; Humans ; Injections ; Ophthalmic Solutions - analysis ; Ophthalmic Solutions - chemistry ; Ophthalmic Solutions - isolation & purification ; Triamcinolone Acetonide - analysis ; Triamcinolone Acetonide - chemistry ; Triamcinolone Acetonide - isolation & purification ; Vitreous Body</subject><ispartof>Japanese journal of ophthalmology, 2005-09, Vol.49 (5), p.384-387</ispartof><rights>Japanese Ophthalmological Society 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-e8a8de078503c12e75b55d9af3350a02a3e34a99a6d6cd015faf34c351aca81e3</citedby><cites>FETCH-LOGICAL-c441t-e8a8de078503c12e75b55d9af3350a02a3e34a99a6d6cd015faf34c351aca81e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16187038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oishi, Masako</creatorcontrib><creatorcontrib>Maeda, Shinichiro</creatorcontrib><creatorcontrib>Nakamura, Ayumi</creatorcontrib><creatorcontrib>Kurokawa, Nobuo</creatorcontrib><creatorcontrib>Ohguro, Nobuyuki</creatorcontrib><creatorcontrib>Tano, Yasuo</creatorcontrib><title>Examination of purification methods and development of intravitreal injection of triamcinolone acetonide</title><title>Japanese journal of ophthalmology</title><addtitle>Jpn J Ophthalmol</addtitle><description>Intravitreal injection of triamcinolone acetonide (TA) is used in ophthalmic treatment, but the reliability of commercially available TA preparations has still not been established. We evaluated two previously reported purification methods, and developed a more reliable TA injection which can be prepared in a hospital pharmacy.
We tested the two methods previously reported for purifying commercial TA preparations, the sedimentation and the filtration and backflushing methods. We developed a new TA injection made of pure TA suspended in 0.5% sodium hyaluronate. We measured the TA content in each preparation by high-performance liquid chromatography to evaluate the three methods.
In the sedimentation purification method, the TA content of a nominal 4-mg preparation varied from 1.43 to 7.37 mg, and the average recovery rate was 91.6%. In the filtration and backflushing method, TA content was 0.10-10.33 mg and recovery was 59.5%. In the TA injection we developed, the mean TA content was 102.5% (SD, 0.24; CV, 2.9%). The stability of this preparation was 99% after sterilization, and 97% after 3 months of storage.
The results of our investigation showed that the purification methods used for commercial preparations are simple and easy but not precise enough for an intravitreal injection. In contrast, the TA injection prepared by our method is reliable, stable, and safe enough for clinical use.</description><subject>Chromatography, High Pressure Liquid</subject><subject>Glucocorticoids - analysis</subject><subject>Glucocorticoids - chemistry</subject><subject>Glucocorticoids - isolation & purification</subject><subject>Humans</subject><subject>Injections</subject><subject>Ophthalmic Solutions - analysis</subject><subject>Ophthalmic Solutions - chemistry</subject><subject>Ophthalmic Solutions - isolation & purification</subject><subject>Triamcinolone Acetonide - analysis</subject><subject>Triamcinolone Acetonide - chemistry</subject><subject>Triamcinolone Acetonide - isolation & purification</subject><subject>Vitreous Body</subject><issn>0021-5155</issn><issn>1613-2246</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpdkU1LBDEMhosoun78AC8yePA2mrbT2dmjiF8geNFziW0Gu8y0a9sR_fd22RXBQwghz_sS8jJ2yuGSA8yvEgfZNTVAKSHaGnbYjLdc1kI07S6bAQheK67UATtMaQkFFFLss4MCdfOinbH32y8cncfsgq9CX62m6HpnNvNI-T3YVKG3laVPGsJqJJ_XnPM54qfLkXAow5LMr0OODkfjfBiCpwoN5eCdpWO21-OQ6GTbj9jr3e3LzUP99Hz_eHP9VJum4bmmDjtLMO8USMMFzdWbUnaBvZQKEARKkg0uFtja1ljgqi-rxkjF0WDHSR6xi43vKoaPiVLWo0uGhgE9hSnptmuFahtewPN_4DJM0ZfbtJBcKCHVokB8A5kYUorU61V0I8ZvzUGvM9CbDHR5rV5noKFozrbG09tI9k-xfbr8Ab9Og5s</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>Oishi, Masako</creator><creator>Maeda, Shinichiro</creator><creator>Nakamura, Ayumi</creator><creator>Kurokawa, Nobuo</creator><creator>Ohguro, Nobuyuki</creator><creator>Tano, Yasuo</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20050901</creationdate><title>Examination of purification methods and development of intravitreal injection of triamcinolone acetonide</title><author>Oishi, Masako ; Maeda, Shinichiro ; Nakamura, Ayumi ; Kurokawa, Nobuo ; Ohguro, Nobuyuki ; Tano, Yasuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-e8a8de078503c12e75b55d9af3350a02a3e34a99a6d6cd015faf34c351aca81e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Chromatography, High Pressure Liquid</topic><topic>Glucocorticoids - analysis</topic><topic>Glucocorticoids - chemistry</topic><topic>Glucocorticoids - isolation & purification</topic><topic>Humans</topic><topic>Injections</topic><topic>Ophthalmic Solutions - analysis</topic><topic>Ophthalmic Solutions - chemistry</topic><topic>Ophthalmic Solutions - isolation & purification</topic><topic>Triamcinolone Acetonide - analysis</topic><topic>Triamcinolone Acetonide - chemistry</topic><topic>Triamcinolone Acetonide - isolation & purification</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oishi, Masako</creatorcontrib><creatorcontrib>Maeda, Shinichiro</creatorcontrib><creatorcontrib>Nakamura, Ayumi</creatorcontrib><creatorcontrib>Kurokawa, Nobuo</creatorcontrib><creatorcontrib>Ohguro, Nobuyuki</creatorcontrib><creatorcontrib>Tano, Yasuo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection (ProQuest Medical & Health Databases)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oishi, Masako</au><au>Maeda, Shinichiro</au><au>Nakamura, Ayumi</au><au>Kurokawa, Nobuo</au><au>Ohguro, Nobuyuki</au><au>Tano, Yasuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Examination of purification methods and development of intravitreal injection of triamcinolone acetonide</atitle><jtitle>Japanese journal of ophthalmology</jtitle><addtitle>Jpn J Ophthalmol</addtitle><date>2005-09-01</date><risdate>2005</risdate><volume>49</volume><issue>5</issue><spage>384</spage><epage>387</epage><pages>384-387</pages><issn>0021-5155</issn><eissn>1613-2246</eissn><abstract>Intravitreal injection of triamcinolone acetonide (TA) is used in ophthalmic treatment, but the reliability of commercially available TA preparations has still not been established. We evaluated two previously reported purification methods, and developed a more reliable TA injection which can be prepared in a hospital pharmacy.
We tested the two methods previously reported for purifying commercial TA preparations, the sedimentation and the filtration and backflushing methods. We developed a new TA injection made of pure TA suspended in 0.5% sodium hyaluronate. We measured the TA content in each preparation by high-performance liquid chromatography to evaluate the three methods.
In the sedimentation purification method, the TA content of a nominal 4-mg preparation varied from 1.43 to 7.37 mg, and the average recovery rate was 91.6%. In the filtration and backflushing method, TA content was 0.10-10.33 mg and recovery was 59.5%. In the TA injection we developed, the mean TA content was 102.5% (SD, 0.24; CV, 2.9%). The stability of this preparation was 99% after sterilization, and 97% after 3 months of storage.
The results of our investigation showed that the purification methods used for commercial preparations are simple and easy but not precise enough for an intravitreal injection. In contrast, the TA injection prepared by our method is reliable, stable, and safe enough for clinical use.</abstract><cop>Japan</cop><pub>Springer Nature B.V</pub><pmid>16187038</pmid><doi>10.1007/s10384-004-0226-0</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-5155 |
ispartof | Japanese journal of ophthalmology, 2005-09, Vol.49 (5), p.384-387 |
issn | 0021-5155 1613-2246 |
language | eng |
recordid | cdi_proquest_miscellaneous_68625641 |
source | Springer Nature |
subjects | Chromatography, High Pressure Liquid Glucocorticoids - analysis Glucocorticoids - chemistry Glucocorticoids - isolation & purification Humans Injections Ophthalmic Solutions - analysis Ophthalmic Solutions - chemistry Ophthalmic Solutions - isolation & purification Triamcinolone Acetonide - analysis Triamcinolone Acetonide - chemistry Triamcinolone Acetonide - isolation & purification Vitreous Body |
title | Examination of purification methods and development of intravitreal injection of triamcinolone acetonide |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T09%3A42%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Examination%20of%20purification%20methods%20and%20development%20of%20intravitreal%20injection%20of%20triamcinolone%20acetonide&rft.jtitle=Japanese%20journal%20of%20ophthalmology&rft.au=Oishi,%20Masako&rft.date=2005-09-01&rft.volume=49&rft.issue=5&rft.spage=384&rft.epage=387&rft.pages=384-387&rft.issn=0021-5155&rft.eissn=1613-2246&rft_id=info:doi/10.1007/s10384-004-0226-0&rft_dat=%3Cproquest_cross%3E68625641%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c441t-e8a8de078503c12e75b55d9af3350a02a3e34a99a6d6cd015faf34c351aca81e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=231252359&rft_id=info:pmid/16187038&rfr_iscdi=true |